Grethe Nørskov Rasmussen
Corporate Officer/Principal presso FLUOGUIDE A/S
Patrimonio netto: 2 M $ in data 31/03/2024
Profilo
Grethe Nørskov Rasmussen is currently the Chief Development Officer at FluoGuide A since 2019.
Prior to this, she was the Senior Vice President-Product Development at Ascendis Pharma A from 2008 to 2019.
Before that, she worked as the Vice President-Protein Science at Maxygen, Inc. from 2000 to 2007 and as a Principal at Novo Nordisk A from 1989 to 2000.
Dr. Rasmussen earned her doctorate degree from the Technical University of Denmark in 1989.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
FLUOGUIDE A/S
3.06% | 30/09/2023 | 373 185 ( 3.06% ) | 2 M $ | 31/03/2024 |
Posizioni attive di Grethe Nørskov Rasmussen
| Società | Posizione | Inizio |
|---|---|---|
| FLUOGUIDE A/S | Corporate Officer/Principal | 01/01/2019 |
Precedenti posizioni note di Grethe Nørskov Rasmussen
| Società | Posizione | Fine |
|---|---|---|
| ASCENDIS PHARMA A/S | Corporate Officer/Principal | 01/01/2019 |
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Corporate Officer/Principal | - |
| NOVO NORDISK A/S | Corporate Officer/Principal | - |
Formazione di Grethe Nørskov Rasmussen
| Technical University of Denmark | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| NOVO NORDISK A/S | Health Technology |
| ASCENDIS PHARMA A/S | Health Technology |
| FLUOGUIDE A/S | Health Technology |
| Aziende private | 1 |
|---|---|
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Commercial Services |
- Borsa valori
- Insiders
- Grethe Nørskov Rasmussen
